ArticleDrug delivery and translational research2011
Non-viral systemic delivery of siRNA or antisense oligonucleotides targeted to Jun N-terminal kinase 1 prevents cellular hypoxic damage.
Article in Drug delivery and translational research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 20 citations in OpenAlex.
- Lipid-Drug Conjugates and Nanoparticles for the Cutaneous Delivery of Cannabidiol.International journal of molecular sciences · 2022Review
- Multifunctional and stimuli-responsive nanocarriers for targeted therapeutic delivery.Expert opinion on drug delivery · 2021Review
- Targeted Nanotherapeutics for Respiratory Diseases: Cancer, Fibrosis, and Coronavirus.Advanced therapeutics · 2021Review
- Strategy to enhance lung cancer treatment by five essential elements: inhalation delivery, nanotechnology, tumor-receptor targeting, chemo- and gene therapy.Theranostics · 2019Article
- Targeted nanomedicine for suppression of CD44 and simultaneous cell death induction in ovarian cancer: an optimal delivery of siRNA and anticancer drug.Clinical cancer research : an official journal of the American Association for Cancer Research · 2013Article
- Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA.Journal of controlled release : official journal of the Controlled Release Society · 2013Article
- Inhalation treatment of pulmonary fibrosis by liposomal prostaglandin E2.European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 2013Article
- Genotoxicity of different nanocarriers: possible modifications for the delivery of nucleic acids.Current drug discovery technologies · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Many pathological conditions and environmental impacts lead to the development of severe tissue hypoxia that aggravates the primary disorder, provokes cell death, and limits the patient's recovery. We hypothesized that suppression of Jun N-terminal kinase 1 (JNK1) will limit tissue damage induced by severe hypoxia. To test the hypothesis, antisense oligonucleotides (ASO) or small interfering RNA (siRNA) targeted to JNK1 mRNA were incorporated or complexed with neutral or cationic liposomes, respectively, and administered systemically to mice prior to hypoxia exposure. The animals were placed in a special chamber ventilated with room air (normoxia) or a gas mixture containing 6% O(2) and 94% N(2) (hypoxia). Liposomes, ASO, and siRNA were found to accumulate in the lungs, kidney, spleen, and heart. Only trace amounts of liposomes and their payloads (ASO and siRNA) were found in the brain. The down regulation of JNK1 protein limited activation of cell death signal, apoptotic, and necrotic tissue damage under hypoxic conditions. Consequently, we were able to verify our hypothesis and provide proof of concept of a unique approach to the prevention of cellular hypoxic damage by the suppression of JNK1 signaling pathways after the efficient delivery of ASO or siRNA.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.